22
2023-08
Suzhou, August 22, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 180 patients for the Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera (PROTAC) compound GT20029 in China for the treatment of male androgenetic alopecia (AGA). GT20029 was developed based on the in-house PROTAC platform and is the world’s first topical PROTAC compound which has entered the Phase II clinical stage.
19
2023-07
Suzhou, July 19, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today. The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023.
11
2023-05
Suzhou, May 11, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia (“AGA”) in the US has been completed successfully. The results are statistically and clinically meaningful, and demonstrated a favorable safety profile. The company is preparing for subsequent FDA meetings on the results of the Phase II clinical trial, and intends to commence Phase III clinical trial in the US/globally.
08
2023-05
Suzhou, May 8, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase I clinical trial of in-house developed GT1708F (Hedgehog/SMO Inhibitor) for treatment of hematologic malignancies in China has been successfully completed. The result showed that GT1708F has demonstrated a good safety and tolerability profile, and all patients experienced no dose-limiting toxicity (the “DLT”) or drug-related serious adverse events (the “SAE”). Preliminary efficacy was observed starting from 180mg dose level in dose escalation stage for patients with acute myeloid leukemia (the “AML”) who failed multi-line therapies, and the myeloid blasts decreased by up to 62% compared to the baseline in AML patients.
14
2023-04
Suzhou, April 14, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the first patient enrollment in Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera (PROTAC) compound GT20029 in China for the treatment of male androgenetic alopecia (AGA). GT20029 is the world’s first topical PROTAC compound which entered the Phase II clinical stage.
30
2023-03
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress
Suzhou, March 30, 2023 - Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn